Biomarkers in cancer: is ‘omices’ the way to go by Buhmeida, Abdelbaset & Ali, Peer Zada Abdul
Biomarkers in cancer: is ‘omices’ the
way to go
B
iomarkers, as indicators of normal biological
or pathogenic processes or pharmacological re-
sponses to a therapeutic intervention (1), have
been reported to be useful prognostic and predictive
markers of cancer diseases (1, 2). The past decade has
witnessed major advances toward biomarker discovery;
however, only a few biomarkers have made their way
into clinical routine such as estrogen receptor (ER)
and human epidermal growth factor receptor 2 (HER2)
(2). The ER-positive patients with breast cancer res-
pond to ER antagonist, Tamoxifen; whereas ER-negative
patients do not benefit from Tamoxifen treatment.
HER2-positive patients respond well to a humanized
monoclonal antibody against the extracellular domain
of HER2, Herceptin, whereas HER2-negative patients
do not.
The study of biomarkers has gained impetus in part
due to advances in high-throughput technologies such
as microarray-based genomics, mass spectrometry-based
proteomics, and next generation sequencing concomitant
with the development of advanced bioinformatics tools.
These high-throughput techniques commonly referred
as ‘omices’ have been vital in our understanding of the
molecular regulatory pathways and networks involved
in specific disease pathogenesis and in examining com-
plete complements of genes or proteins. Other potential
areas in ‘omics’ include transcriptomics, metabolomics,
metabonomics glycomics, interactomics, kinomics, and
microRNAomics.
The global high-throughput techniques have been
actively applied to the molecular analysis of various
human cancers such as bladder, colorectal, breast, sto-
mach, and liver cancers and leukemias. However, high-
throughput genotyping or proteomic studies have not
been reported comprehensively from the Arab world
including Libya. In order to maximize progress in
research with a vision to improve the health standards
nationwide, we need to move forward in a collective and
dedicated manner and push for the development and
application of innovative technologies in national research
institutions. The goal is to implement those technologies
in obtaining the disease-relevant knowledge that can be
tailored for specific diagnostic or therapeutic purposes.
Once this has been achieved, the research findings may
be translated into clinical applications, for example,
by providing new biomarkers for early disease detec-
tion (diagnostic markers), survival outcome (prognostic
markers), treatment responses (predictive markers), and
disease recurrence (monitoring markers) specific for the
population (3, 4).
In the days of ‘personalized medical care’, identifi-
cation of population-specific biomarkers constitutes a
road-map that may be harnessed for achieving short-
term and long-term goals of personalized medicine. We
recently showed significant differences at the genomic
and protein level when the comparison was made bet-
ween Saudi and non-Saudi populations at the Center
of Excellence in Genomic Medicine (CEGMR), Jeddah,
Saudi Arabia (5, 6). These studies warrant investigation
in other parts of the Arab world. Currently, only a
few clinical biomarkers and specific diagnostic tests are
available across the globe pointing to the need, in general,
for the development of novel biomarkers in many areas
of health care. Without specific and reliable biomarkers,
diseases such as cancer will remain undetected early-on
that will in turn affect therapeutic response in the cancer
patients (7).
Measurement of the expression of genes (mRNA expres-
sion) such as microarray and quantitative polymerase
chain reaction (PCR) have been well developed and
extensively used in genomics approaches of biomarker
studies. Affymetrix and Agilent-based microarray platforms
are widely used for expression analysis. Array-based com-
parative genomic hybridization (aCGH) is now accepted
technology to determine copy-number variations of the
whole genome in a single experiment. It is presumed that
a CGH will replace conventional cytogenetics (karyotyping
and fluorescent in situ hybridization, FISH) for diagnostic
purposes. Massively parallel sequencing or next genera-
tion sequencing (NGS) technology is another addition to
genomic approaches. Mass spectrometry (MS) is the major
technology used in proteomics approaches of biomarker
s t u d i e s .L a b e l - f r e eo rl a b e l i n ga p p r o a c h e ss u c ha st h o s e
b a s e do nS I L A Cc a nb eu t i l i z e df o rq u a n t i f i c a t i o nf o l l o w e d
by multidimensional liquid chromatography (LC) coupled
to mass spectrometry (MS) based on electrospray ioniza-
tion (ESI) or matrix-assisted laser desorption ioniza-
tion (MALDI) ion sources. In addition to genomics and
proteomics approaches, pharmacogenomics and metabo-
nomics can address studies in response to a variety of
stimuli including drugs. It may be important to mention
here that all these methods are incomplete in identifying
novel biomarkers without powerful supercomputing analy-
sis methods, artificial intelligence-based tools, and statistical
tools.
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technologies are we going to adopt to get the best
results in terms of biomarkers? Mass spectrometry-based
clinical proteomics has an advantage of enabling
researchers to work on the level of gene products, the
proteins, which are more dynamic and complex than
genome. The studies based on DNA or RNA becomes
equally important for molecular diagnostics when dealing
with clinical samples. In this direction, high-throughput
sequencing technologies (next generation sequencing
or NGS) are currently being utilized for targeted
sequencing of candidate genes or genomic intervals to
perform sequence-based association studies since they
are able to generate three to four orders of magnitude
more sequence than the previous methodologies. Further-
more, detection of single nucleotide polymorphisms
(SNPs) and other novel variants that have been reported
as essential to predispose individuals to neoplasms gives
NGS technologies an added advantage. Genome-wide
SNP arrays can be utilized to investigate chromosomal
defects and molecular abnormalities and address the
issues of clonality in human cancers that may be
of familial type (e.g. familial breast cancer or familial
myeloproliferative neoplasms). While these technologies
may work at the individual level in addressing certain
problems, integrative approaches seem more feasible in
terms of biomarker discovery.
In the above context with rapid developments in
the high-throughput technologies, the other question is:
are we able to bridge the gap between the ‘bench and the
bed-side’ by enhancing cooperation among clinicians,
research scientists and computational biologists? This
becomes entirely essential in particular, with a massive
scale of data generated using high-throughput technolo-
gies along with the number of different protocols,
platforms, and analysis methods that make these studies
difficult for clinicians to comprehend. Another essential
factor that will have a direct impact on the specificity and
sensitivity of a biomarker is proper and adequate sample
handling procedures. Clear-cut policies and protocols
need to be formulated for sample handling and storage
among various collaborative centers in order to achieve
reliable and reproducible results.
In summary, we strongly believe that emphasis
on research innovation toward biomarker discovery and
education will continue to alleviate human suffering from
common diseases thereby providing better health care.
Abdelbaset Buhmeida
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